Compare SWZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWZ | STRO |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 85.0M |
| IPO Year | N/A | N/A |
| Metric | SWZ | STRO |
|---|---|---|
| Price | $5.90 | $20.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 68.1K | ★ 126.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $0.52 |
| 52 Week High | $9.43 | $27.96 |
| Indicator | SWZ | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 49.59 |
| Support Level | $5.88 | $0.76 |
| Resistance Level | $6.10 | $27.96 |
| Average True Range (ATR) | 0.07 | 2.19 |
| MACD | -0.01 | -0.58 |
| Stochastic Oscillator | 14.29 | 21.58 |
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.